Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing.
Ryerson LZ, Foley J, Chang I, Kister I, Cutter G, Metzger RR, Goldberg JD, Li X, Riddle E, Smirnakis K, Kasliwal R, Ren Z, Hotermans C, Ho PR, Campbell N.
Ryerson LZ, et al. Among authors: campbell n.
Neurology. 2019 Oct 8;93(15):e1452-e1462. doi: 10.1212/WNL.0000000000008243. Epub 2019 Sep 12.
Neurology. 2019.
PMID: 31515290
Free PMC article.